New phishing tactics are abusing trusted domains, real CAPTCHAs, and server-side email validation to selectively target ...

CHP says its newly-designed fleet will give them an "important advantage" by being able to blend into traffic without ...

Here’s a brief dive into the murky waters of shape-shifting attacks that leverage dedicated phishing kits to auto-generate ...

Companies' hesitation to take part in Pride is reminiscent of their silence during Black History Month in February, according ...

Their feminine decree goes something like this: Get married young, have as many babies as you can while you’re at peak ...

It is the final week of February 2024, and the City of London, the capital’s ancient financial district, where corporations ...

In April 2025, the Company announced that the first patient had been dosed in Part 2a of the Phase 2 DENALI clinical trial ( NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ...

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its ...

Q3 2025 Earnings Call Transcript May 6, 2025 Intapp, Inc. beats earnings expectations. Reported EPS is $0.26, expectations ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...